SAFC Expands PharmaGrade Raw Materials Portfolio for Biopharmaceutical Manufacturing
ST. LOUIS, Nov. 13, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), has added more than 25 new raw materials to its portfolio of PharmaGrade products. Launched earlier this year, the PharmaGrade portfolio is comprised of over 65 high-quality buffers, amino acids and specialty chemicals, addressing the need for greater supply chain transparency and enhanced risk management for biopharmaceutical manufacturing. PharmaGrade products come with a fully documented production history that highlights consistent and controlled processes compliant with GMP or SAFC 'Elite' grade documentation guidelines. All products in the portfolio feature formal manufacturer qualification, quality assurance review and release of every lot, change control notification, as well as quality and regulatory support documentation. For more information on the PharmaGrade portfolio and its complete listing of products, visit www.safcglobal.com/pharmagrade.
"We have had a tremendous response to the introduction of PharmaGrade and the positive benefits it delivers to our customers," stated Deborah Slagle, Vice President of Marketing and Research Development at SAFC. "We are able to offer raw materials that encourage quality by design in the early phases of development, while increasing our customers' and potential customers' confidence in the raw materials they are using. More importantly, this line of products saves time for clients that are looking for hard-to-find products with readily available documentation."
The April 2012 acquisition of Research Organics has enabled SAFC to increase its PharmaGrade offering, while complementing the Company's existing raw materials portfolio. The expanded manufacturing capacity made available by Research Organics also enables SAFC to provide customers with dual sourcing of biological buffers. With the addition of dedicated resources and increased capabilities to the PharmaGrade product line, the transition of Research Organics into SAFC has proven beneficial for customers and successful for SAFC.
"Our goal is simple. We want to be recognized as the supplier of choice within the biopharmaceutical and high technology industries we serve," added Gilles Cottier, President of SAFC. "The acquisition of Research Organics supports us in fulfilling this goal in the biopharmaceutical space and allows us to provide our customers with the kind of quality and supply chain transparency they need. We are pleased that our efficiency in integrating Research Organics capabilities with existing SAFC technologies has brought our customers a substantially increased PharmaGrade materials portfolio in a very short period of time."
The foregoing release contains forward-looking statements that can be identified by terminology such as "tremendous response," "addressing the need," "supports," "allows," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. There can be no guarantee that the SAFC PharmaGrade product offering will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About SAFC: SAFC, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life science and high technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline utilizing its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.safcglobal.com.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology SAFC manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,100 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.
©2012 Sigma-Aldrich Co. LLC. All rights reserved. SAFC and Sigma-Aldrich are trademarks of Sigma-Aldrich Co. LLC.
SOURCE Sigma-Aldrich Corporation
More by this Source
Sigma-Aldrich (NASDAQ: SIAL) Reports Q3 2013 Sales Of $664 Million, Organic Sales Growth Of 5% And Adjusted Diluted EPS Of $1.05. Reaffirms Full Year 2013 Organic Sales Outlook. Narrows Adjusted Diluted EPS Outlook To A New Range Of $4.08 To $4.15
Oct 22, 2013, 07:00 ET
SAFC® Manufacturing New High-Quality PharmaGrade Raw Materials at Arklow, Ireland, Plant
Oct 16, 2013, 07:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.